Agile Therapeutics’ (AGRX) “Buy” Rating Reiterated at HC Wainwright

Agile Therapeutics (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 132.56% from the stock’s previous close.

A number of other brokerages have also weighed in on AGRX. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 price objective on shares of Agile Therapeutics in a research report on Friday, December 22nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, December 28th. Janney Montgomery Scott lowered Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. Finally, William Blair lowered Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Get Agile Therapeutics alerts:

Shares of Agile Therapeutics (NASDAQ:AGRX) opened at $3.44 on Tuesday. Agile Therapeutics has a 1 year low of $1.93 and a 1 year high of $5.60. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGRX. Dimensional Fund Advisors LP lifted its stake in shares of Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after purchasing an additional 82,213 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics in the 2nd quarter valued at approximately $309,000. Royal Bank of Canada lifted its stake in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Agile Therapeutics in the 3rd quarter valued at approximately $943,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Agile Therapeutics in the 3rd quarter valued at approximately $467,000. Institutional investors own 67.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/13/hc-wainwright-reaffirms-buy-rating-for-agile-therapeutics-agrx.html.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.